Acute myelogenous leukemia of unfavourable prognosis treated with retinoic acid, vitamin D3, alpha-interferon and low doses of cytosine arabinoside.
D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002762:Cholecalciferol / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014212:Tretinoin / Q000627:therapeutic use*
D007370:Interferon Type I; D003561:Cytarabine; D002762:Cholecalciferol; D014212:Tretinoin